Andreas Lindauer
Overview
Explore the profile of Andreas Lindauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
191
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lindauer A, Snoeck E, Laveille C, Ayani I, de Monasterioguren L, Almendros M, et al.
J Clin Pharmacol
. 2024 Oct;
65(3):350-360.
PMID: 39417209
Dopamine D2 receptor occupancy (D2RO) significantly influences the clinical effectiveness and safety of many antipsychotic drugs. Maintaining a D2RO range of 65%-80% provides the best antipsychotic effects while minimizing adverse...
2.
Traver E, Rodriguez-Pascau L, Meya U, Pina G, Pascual S, Poli S, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 Mar;
13(6):982-993.
PMID: 38549500
Leriglitazone is a unique peroxisome proliferator-activated receptor-gamma (PPARγ) agonist that crosses the blood-brain barrier in humans and clinical trials have shown evidence of efficacy in neurodegenerative diseases. At clinical doses...
3.
Kanacher T, Lindauer A, Mezzalana E, Michon I, Veau C, Gomez Mantilla J, et al.
Pharmaceutics
. 2020 Dec;
12(12).
PMID: 33302490
Physiologically-based pharmacokinetic (PBPK) modeling is a well-recognized method for quantitatively predicting the effect of intrinsic/extrinsic factors on drug exposure. However, there are only few verified, freely accessible, modifiable, and comprehensive...
4.
Jolling K, Abelo A, Luyckx N, Nandeuil M, Govoni M, Cella M, et al.
CPT Pharmacometrics Syst Pharmacol
. 2019 May;
8(7):460-468.
PMID: 31077576
Concentration-QTcF data obtained from two phase I studies in healthy volunteers treated with a novel phosphodiesterase-4 inhibitor currently under development for the treatment of chronic obstructive pulmonary disease were analyzed...
5.
Time-to-Seizure Modeling of Lacosamide Used in Monotherapy in Patients with Newly Diagnosed Epilepsy
Lindauer A, Laveille C, Stockis A
Clin Pharmacokinet
. 2017 Mar;
56(11):1403-1413.
PMID: 28290119
Objectives: To quantify the relationship between exposure to lacosamide monotherapy and seizure probability, and to simulate the effect of changing the dose regimen. Methods: Structural time-to-event models for dropouts (not...
6.
Kraff S, Lindauer A, Joerger M, Salamone S, Jaehde U
Ther Drug Monit
. 2015 Mar;
37(6):725-32.
PMID: 25774704
Background: Neutropenia is a frequent and severe adverse event in patients receiving paclitaxel chemotherapy. The time above a paclitaxel threshold concentration of 0.05 μmol/L (Tc > 0.05 μmol/L) is a...
7.
Nock V, Lindauer A, Jaehde U, Kloft C
Int J Clin Pharmacol Ther
. 2012 Dec;
51(1):38-40.
PMID: 23259995
No abstract available.
8.
Kanefendt F, Lindauer A, Mross K, Fuhr U, Jaehde U
J Pharm Biomed Anal
. 2012 Jul;
70:485-91.
PMID: 22819208
Soluble VEGFR-3 (sVEGFR-3) is a potential biomarker for the anti-angiogenic activity of tyrosine kinase inhibitors. The aim of this investigation was the validation of an enzyme-linked immunosorbent assay (ELISA) to...
9.
Buss I, Kalayda G, Lindauer A, Reithofer M, Galanski M, Keppler B, et al.
J Biol Inorg Chem
. 2012 Mar;
17(5):699-708.
PMID: 22456982
The purpose of this study was to systematically investigate the relationships between reactivity, cellular accumulation, and cytotoxicity of a panel of oxaliplatin analogues with different leaving groups in human carcinoma...
10.
Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, et al.
Clin Pharmacokinet
. 2011 Aug;
50(9):551-603.
PMID: 21827214
Pyrimidine (imatinib, dasatinib, nilotinib and pazopanib), pyridine (sorafenib) and pyrrole (sunitinib) tyrosine kinase inhibitors (TKIs) are multi-targeted TKIs with high activity towards several families of receptor and non-receptor tyrosine kinases...